Holen Sie sich die Stockscreener-App
41.72
0.17%
0.07
Handel nachbörslich:
41.72
Schlusskurs vom Vortag:
$41.65
Offen:
$41.55
24-Stunden-Volumen:
67,598
Relative Volume:
0.32
Marktkapitalisierung:
$523.21M
Einnahmen:
$52.15M
Nettoeinkommen (Verlust:
$24.35M
KGV:
28.69
EPS:
1.4544
Netto-Cashflow:
$-17.93M
1W Leistung:
+0.43%
1M Leistung:
+10.08%
6M Leistung:
+29.20%
1J Leistung:
+67.89%
1-Tages-Spanne:
$41.55
$41.76
1-Wochen-Bereich:
$41.49
$41.99
52-Wochen-Spanne:
$22.29
$42.81
Xoma Royalty Corp Stock (XOMA) Company Profile
Firmenname
Xoma Royalty Corp
Sektor
Branche
Telefon
510-204-7239
Adresse
2200 POWELL STREET, EMERYVILLE, CA
Compare XOMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
41.72 | 522.33M | 52.15M | 24.35M | -17.93M | 1.4544 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-17 | Eingeleitet | The Benchmark Company | Buy |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2021-09-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-06-29 | Eingeleitet | Aegis Capital | Buy |
| 2021-01-19 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-17 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-05 | Hochstufung | Wedbush | Neutral → Outperform |
| 2017-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-11-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-11 | Bestätigt | Wedbush | Outperform |
| 2015-07-23 | Herabstufung | Jefferies | Buy → Hold |
| 2015-07-22 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2015-07-22 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-10-10 | Fortgesetzt | ROTH Capital | Buy |
| 2014-04-29 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-03-11 | Herabstufung | MLV & Co | Buy → Hold |
| 2014-03-05 | Bestätigt | Ladenburg Thalmann | Buy |
| 2013-10-31 | Bestätigt | MLV & Co | Buy |
| 2013-05-09 | Bestätigt | Ladenburg Thalmann | Buy |
| 2012-05-14 | Eingeleitet | Cowen & Co | Outperform |
| 2011-03-31 | Bestätigt | MLV Capital | Buy |
| 2011-03-23 | Bestätigt | RBC Capital Mkts | Outperform |
| 2011-01-06 | Bestätigt | Ladenburg Thalmann | Buy |
| 2011-01-04 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Xoma Royalty Corp Aktie (XOMA) Neueste Nachrichten
[Form 4] XOMA Royalty Corp Insider Trading Activity - Stock Titan
Director at XOMA (XOMA) granted 3,586 RSUs vesting over 12 months - Stock Titan
Director at XOMA (NASDAQ: XOMA) granted 3,586 RSUs vesting over 12 months - Stock Titan
XOMA Royalty Corp (XOMA) director receives 3,586 RSU equity grant - Stock Titan
Equity grant: XOMA (XOMA) director awarded 3,586 RSUs of common stock - Stock Titan
XOMA Royalty (XOMA) merger: $39.00 cash + one CVR tied to Janssen litigation - Stock Titan
XOMA Royalty Corporation (Formerly XOMA Corp) Files Form 8-K Detailing Bylaws Amendments and Stock Awards – May 2026 - Minichart
XOMA Royalty shareholders approve incentive plan amendments and bylaw changes - Investing.com UK
XOMA (NASDAQ: XOMA) shareholders approve equity plans and new bylaw provisions - Stock Titan
XOMA ROYALTY CORPXOMA 8 3/8 PERP (XOMAO) Stock Price & Overview - ChartMill
XOMAO Stock Price and Chart — NASDAQ:XOMAO - TradingView
BVF group (NASDAQ: XOMA) converts 5,003 Series X preferred into common - Stock Titan
BVF group boosts XOMA (XOMA) ownership to 43.3% after Series X share conversion - Stock Titan
XOMA Royalty amends merger agreement with Ligand Pharmaceuticals By Investing.com - Investing.com Canada
Ligand Pharmaceuticals Files 8-K Announcing Amendment No. 1 to Agreement and Plan of Merger with XOMA Royalty Corporation 10 - Minichart
XOMA Royalty Corp Announces SEC Filing for Merger Agreement with Ligand Pharmaceuticals - Minichart
XOMA Royalty amends merger agreement with Ligand Pharmaceuticals - Investing.com
Ligand Pharmaceuticals amends merger agreement with XOMA Royalty Corporation - Investing.com
XOMA Royalty Amends Ligand Merger Agreement, Adding Holding Company to Advance Acquisition - TradingView
XOMA Royalty (XOMA) adds new holding company to structure of Ligand acquisition - Stock Titan
Ligand (NASDAQ: LGND) amends XOMA Royalty merger, adds Nevada holding company - Stock Titan
XOMA royalty (XOMA) price target decreased by 32.32% to 45.39 - MSN
Woodline (XOMA) reports 640,001-share, 5.4% passive stake in XOMA Royalty - Stock Titan
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Veris Residential, Inc. (NYSE – VRE), XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX) - GlobeNewswire Inc.
XOMA ROYALTY CORP (NASDAQ:XOMAP) Passes Navellier’s Little Book Growth Screen with Strong Momentum - ChartMill
Ligand-Xoma Deal Would Combine Two Royalty Aggregators -- WSJ - Moomoo
XOMA Stock Price, Quote & Chart | XOMA ROYALTY CORPORATION (NASDAQ:XOMA) - ChartMill
TradingKey - TradingKey
Q1 2026: XOMA (NASDAQ: XOMA) profit rises to $4.5M on royalty income - Stock Titan
XOMA Royalty Corporation (NASDAQ:XOMA) Checks Nearly Every Box in Louis Navellier’s Eight-Rule Growth Stock Screen - ChartMill
XOMA Royalty Corporation (NASDAQ:XOMA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
XOMA Royalty CorporationDepositary Shares Rep Series B 8.375% Cumulative Preferred Stock - TradingView
Ligand set to report earnings as XOMA deal reshapes growth outlook - Investing.com
XOMA Royalty (XOMA) Projected to Post Earnings on Tuesday - MarketBeat
XOMA (XOMA) holders offered $39 cash plus CVRs in Ligand buyout - Stock Titan
Ligand Pharmaceuticals Launches Takeover Plan at XOMA Royalty Corporation with 47.0% Stake - TradingView
This Appian Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Thursday - Sahm
[SCHEDULE 13G] XOMA Royalty Corp Passive Investment Disclosure (>5%) - Stock Titan
Weekly Buzz: FDA Okays Saphnelo Pen, EC Clears Acromegaly Drug, SNGX Slumps, LGND Snaps Up XOMA - RTTNews
H.C. Wainwright cuts XOMA stock rating on Ligand acquisition By Investing.com - Investing.com Canada
H.C. Wainwright cuts XOMA stock rating on Ligand acquisition - Investing.com
BVF group backs XOMA Royalty Corp (XOMA) merger with 21.4% locked-up stake - Stock Titan
LGND: XOMA Buy Adds 100+ Assets - Yahoo Finance
XOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law Firm - GlobeNewswire
Ligand to acquire XOMA Royalty - The Pharma Letter
XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last? - Yahoo Finance
Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook - MarketBeat
BlackRock (NASDAQ: XOMA) reports 5.4% stake in XOMA Royalty Corp - Stock Titan
XOMA (XOMA) closes Generation Bio acquisition, details cash-plus-CVR terms and LNP assets - Stock Titan
Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
Finanzdaten der Xoma Royalty Corp-Aktie (XOMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xoma Royalty Corp-Aktie (XOMA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Montano Maricel Perea | Chief Legal Officer |
Apr 20 '26 |
Option Exercise |
0.00 |
3,370 |
0 |
41,793 |
| Hughes Owen | Chief Executive Officer |
Apr 20 '26 |
Option Exercise |
0.00 |
10,568 |
0 |
191,264 |
| Sitko Bradley | Chief Investment Officer |
Apr 20 '26 |
Option Exercise |
0.00 |
3,737 |
0 |
82,961 |
| Trigilio Jeffrey | Chief Financial Officer |
Apr 13 '26 |
Option Exercise |
0.00 |
4,000 |
0 |
94,000 |
| LIMBER JOSEPH M | Director |
Mar 27 '26 |
Option Exercise |
11.20 |
3,026 |
33,891 |
9,234 |
| WYSZOMIERSKI JACK L | Director |
Mar 24 '26 |
Option Exercise |
11.20 |
3,026 |
33,891 |
21,530 |
| Hughes Owen | Chief Executive Officer |
Dec 04 '25 |
Buy |
25.05 |
100,000 |
2,505,000 |
102,000 |
| Sitko Bradley | Chief Investment Officer |
Sep 19 '25 |
Option Exercise |
0.00 |
6,712 |
0 |
19,822 |
| Hughes Owen | Chief Executive Officer |
Sep 19 '25 |
Option Exercise |
0.00 |
35,567 |
0 |
98,268 |
| BURNS THOMAS M. | SVP, Finance & CFO |
Sep 19 '25 |
Option Exercise |
0.00 |
11,846 |
0 |
34,409 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):